Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $145.00

Merck & Co., Inc. (NYSE:MRK) had its target price increased by UBS Group from $130.00 to $145.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Citigroup boosted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, March 20th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Finally, Bank of America lifted their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus price target of $128.47.

Merck & Co., Inc. Stock Down 1.6%

Shares of MRK stock opened at $118.07 on Monday. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock’s fifty day moving average price is $119.26 and its 200 day moving average price is $105.51. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The company has a market cap of $291.62 billion, a price-to-earnings ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the previous year, the business earned $1.72 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Monday, March 16th. Merck & Co., Inc.’s payout ratio is 46.70%.

Insiders Place Their Bets

In other news, CFO Caroline Litchfield sold 41,997 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer owned 90,192 shares of the company’s stock, valued at $10,787,865.12. The trade was a 31.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors and hedge funds have recently modified their holdings of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $25,000. Darwin Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the period. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Finally, Barnes Dennig Private Wealth Management LLC lifted its holdings in shares of Merck & Co., Inc. by 302.3% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after buying an additional 266 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi’s BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. (NYSE:MRK) Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck’s Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA (XTRA:MRK) appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA (XTRA:MRK) Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here’s Why

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.